176 related articles for article (PubMed ID: 35132677)
1. Impact of P-glycoprotein and/or CYP3A4-interacting drugs on effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis.
Grymonprez M; Vanspranghe K; Capiau A; Boussery K; Steurbaut S; Lahousse L
Br J Clin Pharmacol; 2022 Jul; 88(7):3039-3051. PubMed ID: 35132677
[TBL] [Abstract][Full Text] [Related]
2. Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis.
Grymonprez M; Vanspranghe K; Steurbaut S; De Backer TL; Lahousse L
Cardiovasc Drugs Ther; 2023 Aug; 37(4):781-791. PubMed ID: 34637052
[TBL] [Abstract][Full Text] [Related]
3. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.
Grymonprez M; Carnoy L; Capiau A; Boussery K; Mehuys E; De Backer TL; Steurbaut S; Lahousse L
Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):722-730. PubMed ID: 37791408
[TBL] [Abstract][Full Text] [Related]
4. Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis.
Kim IS; Kim HJ; Yu HT; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Pak HN
J Cardiol; 2019 Jun; 73(6):515-521. PubMed ID: 30770140
[TBL] [Abstract][Full Text] [Related]
5. Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation.
Harskamp RE; Teichert M; Lucassen WAM; van Weert HCPM; Lopes RD
Cardiovasc Drugs Ther; 2019 Oct; 33(5):615-623. PubMed ID: 31520256
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
Wang KL; Lopes RD; Patel MR; Büller HR; Tan DS; Chiang CE; Giugliano RP
Eur Heart J; 2019 May; 40(19):1492-1500. PubMed ID: 30590440
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
8. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
[TBL] [Abstract][Full Text] [Related]
9. Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis.
Grymonprez M; De Backer TL; Steurbaut S; Boussery K; Lahousse L
Cardiovasc Drugs Ther; 2022 Aug; 36(4):749-761. PubMed ID: 33428092
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation.
Xiong Q; Lau YC; Lip GY
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):937-48. PubMed ID: 25797167
[TBL] [Abstract][Full Text] [Related]
11. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis.
Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN
J Cardiol; 2018 Oct; 72(4):284-291. PubMed ID: 29706404
[TBL] [Abstract][Full Text] [Related]
12. Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients.
Holm J; Mannheimer B; Malmström RE; Eliasson E; Lindh JD
Eur J Clin Pharmacol; 2021 Mar; 77(3):409-419. PubMed ID: 33029651
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation.
Lupercio F; Romero J; Peltzer B; Maraboto C; Briceno D; Villablanca P; Ferrick K; Gross JN; Kim S; Fisher J; Di Biase L; Krumerman A
Am J Med; 2018 May; 131(5):573.e1-573.e8. PubMed ID: 29274758
[TBL] [Abstract][Full Text] [Related]
14. Concurrent use of P-glycoprotein or Cytochrome 3A4 drugs and non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation.
Sandhu RK; Islam S; Dover DC; Andrade JG; Ezekowitz J; McAlister FA; Hawkins NM; Kaul P
Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):195-201. PubMed ID: 33480405
[TBL] [Abstract][Full Text] [Related]
15. Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review.
Fu Y; Zhu W; Zhou Y; Chen H; Yan L; He W
Am J Cardiovasc Drugs; 2020 Apr; 20(2):139-147. PubMed ID: 31485852
[TBL] [Abstract][Full Text] [Related]
16. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation.
Chang SH; Chou IJ; Yeh YH; Chiou MJ; Wen MS; Kuo CT; See LC; Kuo CF
JAMA; 2017 Oct; 318(13):1250-1259. PubMed ID: 28973247
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients.
Silverio A; Di Maio M; Prota C; De Angelis E; Radano I; Citro R; Carrizzo A; Ciccarelli M; Vecchione C; Capodanno D; Galasso G
Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f20-f29. PubMed ID: 31830264
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
Grymonprez M; Petrovic M; De Backer TL; Steurbaut S; Lahousse L
Thromb Haemost; 2024 Feb; 124(2):135-148. PubMed ID: 37369234
[TBL] [Abstract][Full Text] [Related]
19. The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis.
Yang KT; Sun WC; Tsai TJ; Tsay FW; Chen WC; Cheng JS
Int J Environ Res Public Health; 2020 Dec; 18(1):. PubMed ID: 33375495
[No Abstract] [Full Text] [Related]
20. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Asians With Atrial Fibrillation: Meta-Analysis of Randomized Trials and Real-World Studies.
Xue Z; Zhang H
Stroke; 2019 Oct; 50(10):2819-2828. PubMed ID: 31422735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
